Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of TAS-115 in healthy Japanese male subjects
jRCT2071240021Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pamufetinib in progressive pulmonary fibrosis (PPF) (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Cmax of TAS-115, AUClast of TAS-115 and 1 more. Started Aug 2024; status: completed.
02
Drugs
pamufetinib
03
Conditions
progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on jRCT2071240021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240021.